<DOC>
	<DOC>NCT02981173</DOC>
	<brief_summary>The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen in chronic cluster headache. Subjects will be randomized to receive oral placebo, low dose psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days. Subjects will maintain a headache diary prior to, during, and after the pulse regimen in order to document headache frequency and intensity before, during, and after the pulse regimen.</brief_summary>
	<brief_title>Psilocybin in Chronic Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Psilocybine</mesh_term>
	<criteria>Chronic cluster headache At least one attack daily Attacks respond to highflow oxygen Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis) Axis I psychotic disorder in first degree relative Concomitant diagnosis of migraine headache Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology Pregnant, breastfeeding, lack of adequate birth control History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related compounds drug or alcohol abuse within the past 3 months (excluding tobacco) Urine toxicology positive to drugs of abuse Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) in the past two weeks Use of antidepressant medications (i.e. amitriptyline, isocarboxazid, fluoxetine, citalopram) in the past 6 weeks Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>